The problem of weight loss drugs concerns many people, so pharmaceutical industry every year offers new drug, which guarantees to decrease the body mass. One of those drugs, Qsymia, seems to lose around 5 percent of their body mass over a year its instruction says.
The drug Qsymia combines abilities of phentermine and topiramate, this drug showed fantastic results during clinical tests that covered 30,000 overweight or obese individuals. The analysis pitted prescription drugs phentermine-topiramate (Qsymia), orlistat, lorcaserin (Belviq), naltrexone-bupropion (Contrave) and liraglutide (Saxendra) against each other.
The Food and Drug Administration (FDA) has approved the Qsymia and other drugs like Belviq, Contrave, and Saxendra for weight loss, but patients prefer to take over-the-counter weight loss medication orlistat, which was firstly approved in 1999 by FDA, from then this medicine commercially known as Alli.
In fact, the latest meta-analysis with the figures from 28 clinical trials shows that Qsymia fared best in those reviews, particularly in promoting 5 percent body mass (29,018 patients), 74 percent of whom are women, is 36.1, well into the obese category. In comparison: 75 percents lost 5 percent with Qsymia, 63 percent (Saxendra) and 55 percent (Contrave).
